African American Patients Unnecessarily Excluded From AML Clinical Trials
December 8th 2019Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.
Read More
Mosunetuzumab Produces Complete Remissions in Patients with Non-Hodgkin Lymphoma
December 8th 2019Some patients with non-Hodgkin lymphoma may soon have a treatment option that could offer complete remission, according to new data presented at the American Society of Hematology 2019 Annual Meeting.
Read More
Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup
September 30th 2019Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.
Read More
Frontline Tagrisso Improves Survival Among Specific Subgroup of Patients with NSCLC
September 30th 2019First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.
Read More
Frontline Zejula Maintenance Therapy Improves Survival in Advanced Ovarian Cancer
September 29th 2019Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.
Read More
Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer
September 28th 2019The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.
Read More
Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer
September 28th 2019Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.
Read More
Updated Analysis Supports Evaluation of Second-Line Fedratinib to Treat Myelofibrosis
July 24th 2019Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.
Read More